Valeant Unit to Pay $58 Million to Settle Allegations of Solodyn Pay-for-Delay Scheme

Drug Industry Daily
A A
A Valeant Pharmaceuticals unit agreed to pay $58 million to settle multi-district litigation that accused it of violating antitrust laws to keep generic versions of Solodyn off the market.

To View This Article:

Login

Subscribe To Drug Industry Daily